Thromboembolic and bleeding complications during oral anticoagulation therapy in cancer patients with atrial fibrillation: a Danish nationwide population‐based cohort study

Abstract Coexisting cancer in patients with atrial fibrillation ( AF ) has been associated with thromboembolism and bleeding. We used Danish population‐based medical databases to conduct a population‐based cohort study that included all AF patients who redeemed a prescription for vitamin K antagonists ( VKA ) or non‐ VKA oral anticoagulant ( NOAC ) between July 2004 and December 2013. We characterized these patients according to the presence ( N = 11,855) or absence ( N = 56,264) of a cancer diagnosis before redemption of their oral anticoagulant prescription, and then examined their 1‐year risk of thromboembolic or bleeding complications or death. We next used Cox regression to compare the hazard ratios for complications among VKA ‐ or NOAC ‐treated AF patients with versus without a cancer diagnosis, after adjusting for sex, age, and CHA 2 DS 2 VAS c score. One‐year risks of thromboembolic complications in AF patients who redeemed a VKA prescription were similar in those with (6.5%) and without (5.8%) cancer hazard ratio ( HR ) 1.0 (95% confidence interval ( CI ): 0.93, 1.1). This also was found for bleeding complications (5.4% vs. 4.3%, HR 1.1 95% CI : 1.0, 1.2). For AF patients with cancer who redeemed a NOAC prescription, risks were also similar for thromboembolic complications (4.9% of cancer patients vs. 5.1% of noncancer patients, HR 0.80 95% CI : 0.61, 1.1), and for bleeding complications (4.4% vs. 3.1%, HR 1.2 95% CI : 0.92, 1.7). The absolute risks of thromboembolic or bleeding complications were nearly the same in patients with and without cancer who redeemed prescription for VKA s or NOAC s.